Holen Sie sich die Stockscreener-App
5.09
3.46%
0.17
Handel nachbörslich:
5.11
0.02
+0.39%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt MYGN?
Forum
Prognose
Aktiensplit
Myriad Genetics Inc Aktie (MYGN) Neueste Nachrichten
3 Reasons to Avoid MYGN and 1 Stock to Buy Instead - FinancialContent
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Myriad Genetics (MYGN) Investors Who Suffered Significant Losses to Contact Its Attorneys, Application Deadline is Approaching - ACCESS Newswire
Myriad (MYGN) Up 23.9% Since Last Earnings Report: Can It Continue? - Yahoo Finance
7-DAY DEADLINE ALERT: HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Myriad Genetics (MYGN) Investors Who Suffered Significant Losses to Contact Its Attorneys, Application Deadline is Approaching - ACCESS Newswire
Myriad Genetics Announces Early Access to the FirstGene Multiple Prenatal Screen - GlobeNewswire
FINAL DEADLINE ALERT: HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Myriad Genetics (MYGN) Investors Who Suffered Significant Losses to Contact Its Attorneys, Application Deadline Tomorrow - ACCESS Newswire
Trend Tracker for (MYGN) - news.stocktradersdaily.com
US Direct-To-Consumer Genetic Testing Market Report 2025, - GlobeNewswire
US Direct-To-Consumer Genetic Testing Market Report 2025, Competitive Analysis of 23andMe, Gene by Gene, Ancestry, Genesis, EasyDNA, Veritas, Myriad Genetics, Taconic Biosciences, & Color Health - Yahoo Finance
Myriad Genetics (MYGN) Launches FirstGene Multiple Prenatal Screen | MYGN Stock News - GuruFocus
Myriad Genetics Launches FirstGene™ Prenatal Screen for Comprehensive Genetic Risk Assessment in One Blood Draw - Nasdaq
Breakthrough Prenatal Screen Combines 4 Tests in 1 Blood DrawNo Father Sample Needed - Stock Titan
Hereditary Testing MarketGlobal Industry Trends, - GlobeNewswire
MYGN INVESTOR REMINDER: Hagens Berman Reminds Myriad Genetics (MYGN) Investors of Securities Fraud Lawsuit, Encourages Investors Who Lost $50,000+ to Contact the Firm - ACCESS Newswire
Myriad Genetics to Announce December 2020 Quarterly Financial Results on February 23, 2021 - GlobeNewswire
Myriad Genetics Reports Ultra-Sensitive CtDNA Detection With Precise MRD In Pan-Cancer Study - Nasdaq
Myriad Genetics (MYGN) Reports Promising Results from MONSTAR-SCREEN 3 Study | MYGN Stock News - GuruFocus
Myriad Genetics Shares New Clinical Data Demonstrating Sensitivity of Precise MRD Across Multiple Cancer Types - GlobeNewswire
Breakthrough: Myriad Genetics New Cancer Test Detects Tumors 60% Better Than First-Gen Tests - Stock Titan
Ameriprise Financial Inc. Has $2.88 Million Stock Position in Myriad Genetics, Inc. (NASDAQ:MYGN) - Defense World
Myriad Genetics, Inc. (MYGN) Showcases Breakthrough MRD Data and AI-Driven Cancer Tools at ASCO 2025 - Insider Monkey
Myriad Genetics Highlights New Research Advancements and Oncolog - GuruFocus
Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting | MYGN Stock News - GuruFocus
Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting - GlobeNewswire
Spotting Winners: Myriad Genetics (NASDAQ:MYGN) And Therapeutics Stocks In Q1 - Yahoo Finance
Man Group plc Makes New $390,000 Investment in Myriad Genetics, Inc. (NASDAQ:MYGN) - Defense World
Bronstein, Gewirtz & Grossman, LLC Is Investigating Myriad Genetics, Inc. (MYGN) And Encourages Shareholders to Connect - ACCESS Newswire
Deutsche Bank AG Purchases 27,541 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN) - Defense World
Hereditary Cancer Testing Market Size | Industry Report 2030 - Grand View Research
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Myriad Genetics, Inc. (MYGN) And Encourages Shareholders to Reach Out - ACCESS Newswire
Levi & Korsinsky Investigates Myriad Genetics, Inc. (MYGN) Over Possible Securities Fraud - ACCESS Newswire
Trading (MYGN) With Integrated Risk Controls - news.stocktradersdaily.com
ATTENTION MYGN Shareholders: Lost Money on Myriad Genetics, Inc.? Contact Levi & Korsinsky About Investigation - ACCESS Newswire
Scotiabank Downgrades Myriad Genetics (NASDAQ:MYGN) to Sector Perform - Defense World
Microtomes Market Generated Opportunities, Future Scope - openPR.com
Parp Inhibitor Biomarkers Market Generated Opportunities, - openPR.com
BNP Paribas Financial Markets Purchases 23,408 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN) - Defense World
Captrust Financial Advisors Grows Stock Position in Myriad Genetics, Inc. (NASDAQ:MYGN) - Defense World
Myriad Genetics Shares Fall After Downgrade From Scotiabank - marketscreener.com
Myriad Genetics, Inc. (MYGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Genetic Counseling Market Deep Research Report with Forecast by 2032 | Invitae Corporation, Myriad Genetics - openPR.com
Myriad Genetics (MYGN) Faces Downgrade and Price Target Reduction | MYGN Stock News - GuruFocus
This UnitedHealth Group Analyst Turns Bearish; Here Are Top 3 Downgrades For Wednesday - Benzinga
Scotiabank Downgrades Myriad Genetics (MYGN) With Revised Price - GuruFocus
Myriad Genetics, Inc. (NASDAQ:MYGN) Receives Consensus Recommendation of “Hold” from Brokerages - Defense World
Scotiabank Downgrades Myriad Genetics (MYGN) Rating | MYGN Stock News - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Is Investigating Myriad Genetics, Inc. (MYGN) And Encourages Investors to Connect - ACCESS Newswire
Myriad Genetics (MYGN) Faces Downgrade Amidst Challenging Quarte - GuruFocus
Myriad Genetics (MYGN) Faces Price Target Cut After Q1 Miss | MY - GuruFocus
Levi & Korsinsky Investigates Possible Securities Fraud by Myriad Genetics, Inc. (MYGN) - ACCESS Newswire
Morgan Stanley Cuts Price Target on Myriad Genetics to $7 From $16, Maintains Equalweight Rating - marketscreener.com
MYGN Q1 Earnings Call: Guidance Cut Amid GeneSight Challenges and Slow Hereditary Cancer Ramp - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Myriad Genetics, Inc. (MYGN) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
0.40%
1.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):